KARL STORZ Installs Advanced blue Light Cystoscopy System at Naval Medical Center San Diego
07/09/2016 | 企业概况
New Technology Provides Enhanced Capabilities for Diagnosis of Non-Muscle Invasive Bladder Cancer
EL SEGUNDO, CA (September 7, 2016) – KARL STORZ Endoscopy-America, Inc., a leader in minimally invasive endoscopy and advanced imaging solutions, is pleased to announce that it has installed an innovative technology system for providing Blue Light Cystoscopy (BLC) with Cysview® at the Naval Medical Center San Diego (NMCSD). The medical center is the first Naval Medical Center to offer this new technology, which provides advanced capabilities for diagnosis of Non-Muscle Invasive Bladder Cancer (NMIBC). Blue Light Cystoscopy uses the KARL STORZ D-Light C Photodynamic Diagnostic system in conjunction with Cysview®, a special optical imaging agent.
“We are very proud to offer this advanced cystoscopy system to the Naval Medical Center in San Diego,” says John Martineau, Director of Marketing Urology, KARL STORZ. “We consider it an honor to support the world-class level of care and treatment that the physicians and surgeons offer to our nation’s service personnel and their family members.”
The American Urological Association (AUA) and the Society of Urological Oncology (SUO) recently included enhanced cystoscopy in the 2016 Guidelines for the management of non-muscle invasive bladder cancer (NMIBC). Enhanced cystoscopy (including Blue Light Cystoscopy with Cysview/Hexvix) is recommended for increasing the detection and reducing recurrence of NMIBC. The full guidelines are available for review at Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline, 2016.
What is blue Light Cystoscopy with Cysview®?
BLC uses the D-Light C Photodynamic Diagnostic (PDD) system along with Cysview®, an optical imaging agent. The combined system is used to enhance the detection and management of Non-Muscle Invasive Bladder Cancer (NMIBC) in patients with known or suspected bladder cancer, based on prior cystoscopy. Use of the technology begins with placement of Cysview® into the bladder prior to the procedure, where it accumulates in tumor cells and is converted into porphyrins within the tumor. When viewed with the D-Light C PDD system, the tumor cells appear red or pink in contrast with the normal cells, which appear blue in color. The system is capable of delivering both conventional white light to illuminate the bladder during routine cystoscopy, as well as a special blue light to induce and view fluorescence after the placement of Cysview®.
Cysview® is a registered trademark of Photocure, Inc.